BioCryst Pharmaceuticals Appoints Babar Ghias as New CFO

BioCryst Pharmaceuticals has appointed Babar Ghias as Chief Financial Officer. The company focuses on developing treatments for rare diseases, including hereditary angioedema and influenza. Its marketed products include ORLADEYO and RAPIVAB. Ghias brings experience from Bloomberg and will oversee the company's financial strategy.

BioCryst Pharmaceuticals (BCRX) has announced the appointment of Babar Ghias as its new Chief Financial Officer (CFO) and head of corporate development. Ghias joins the company from AvenCell Therapeutics, where he served as CFO since 2022. Prior to AvenCell, Ghias held various executive roles at Paragon Biosciences and Marathon Pharmaceuticals, demonstrating extensive experience in biotechnology, rare disease companies, and capital deployment [1][2].

Ghias brings a robust background in deal making, operational management, and financial strategy. He previously launched four biotechnology companies at Paragon Biosciences and raised over $1 billion in capital for various companies. His experience includes serving as a senior member of the mergers and acquisitions team at Credit Suisse, where he successfully closed over $80 billion in transactions. Ghias holds an M.B.A. with honors from Washington University in St. Louis and a B.S. in economics from Lahore University of Management Sciences in Pakistan [1][2].

BioCryst Pharmaceuticals specializes in developing first-in-class and best-in-class oral small-molecule and protein therapeutics for rare diseases. The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. ORLADEYO is currently under FDA review for pediatric hereditary angioedema patients, with potential for significant market acceptance [1].

Ghias' appointment comes at a critical time for BioCryst as the company seeks to deploy capital and accelerate its path to sustainable growth. He will oversee financial strategy and operational excellence, supporting the company's ambitious growth plans. The appointment is part of BioCryst's ongoing efforts to build long-term value and drive operational efficiency [1][2].

References:
[1] https://seekingalpha.com/news/4465546-biocryst-appoints-babar-ghias-as-cfo
[2] https://www.morningstar.com/news/globe-newswire/9489789/biocryst-appoints-babar-ghias-chief-financial-officer-and-head-of-corporate-development